32results about "Platinum group organic compounds without C-metal linkages" patented technology

The invention provides a preparation method of a supramolecular anti-cancer drug (dicycloplatin). The preparation method comprises the following steps of: adding carboplatin and 1,1-cyclobutanedicarboxylic acid into water according to the mol ratio of 1:1, dissolving and uniformly mixing to obtain the mixed solution, and standing the mixed solution in a dark place at the temperature of more than 0 DEG C and less than or equal to 60 DEG C for 3-9 days, and concentrating under reduced pressure or freeze-drying so as to obtain dicycloplatin. The preparation method disclosed by the invention is moderate in condition and environment friendly; both the yield and the purity of dicycloplatin can be up to nearly 100%; the batch yield can reach 1000g; and thus, the preparation method is particularly applied to industrial production.

The present invention discloses an iridium complexes and the organic EL device employing the iridium complexes as light emitting guest of emitting layer can display good performance like as lower driving voltage and power consumption, increasing efficiency and half-life time. Additional, the present invention provide the suitable emitting host (H1 to H6) to collocate with the energy level of iridium complexes for the present invention. Also provided a novel preparation method to synthesize the novel ligand such as 6-bromo-3,3-dimethyl-1-phenyl-1,3-dihydroindeno[2,1-b]carbazole.

The present invention is directed to a method of alleviating, relieving, altering, remedying, ameliorating, improving or affecting a neoplastic disease or an immune disease, the method comprising administering to a subject in need thereof an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof:wherein P, Z, and m are defined herein above.

The invention relates to metal complex compounds of the formula Mk(L)x(Y)kz-nx, where the ligand L has the formula (I), and to metal complex compounds which include the reaction product of at least one salt or a complex of a transition metal or a main group metal element of the groups 13 to 15 and at least one 1,3-ketoamide. Such complex compounds are suitable in particular as catalysts for polyurethane compositions. The invention also relates to two-component polyurethane compositions including at least one polyisocyanate as the first component, at least one polyol as the second component, and at least one such metal complex compound as the catalyst. The invention additionally relates to different uses of the two-component polyurethane compositions.

A metal complex dye having a structure defined by general formula (1) and having either 1 or 2 acid groups. [In general formula (1), A and C have a structure represented by general formula (2), and can be the same as or different to one another. B represents a linking group, and n represents an integer not less than 1. The bond between A and B and the bond between B and C can each be at least bivalent. Additionally, a double bond may be included so as to maintain the resonance structure of the compound. In general formula (2), R1-R8 each independently represents a hydrogen atom, a substituent group, or the bond with B in general formula (1). Among R1-R8, those components which are bonded in the same pyrrole ring can be bonded directly or via another base, and have a cyclic structure. X represents a carbon atom or a nitrogen atom. M represents two hydrogen atoms, two metal atoms or metal oxides, or, one metal atom or metal oxide].

The invention discloses a platinum (II) complex by taking chiral 4-(2,3-dyhydroxylpropyl)-methanamide-6-aza-benzanthrone as a ligand as well as a synthetic method and application of the platinum (II) complex. The synthetic method of the complex comprises the following steps: dissolving (+)-4-(2,3-dyhydroxylpropyl)-methanamide-6-aza-benzanthrone or (-)-4-(2,3-dyhydroxylpropyl)-methanamide-6-aza-benzanthrone and dichloro.bi(dimethyl sulfoxide)mixed platinum (II) in a polar solvent, mixing to carry out a complexing reaction, thereby obtaining the platinum (II) complex. The complex obtained by the inventor has obvious in-vitro antitumor activity, the in-vitro antitumor activity of a tested tumor strain is universally higher than that of an original chiral ligand, and the complex has high potential medicinal value and is expected to be used for preparing various antitumor medicines. The structural formulas of the complex disclosed by the invention are respectively shown in the formulas (I) and (II) in the specification.

Disclosed is a novel catalyst having amine ligands for synthesizing methanol or its precursor. When the catalyst is allowed to react with an alkane in the presence of an acid, at least one C—H bond of the alkane is catalytically oxidized. Therefore, the catalyst is suitable for use in forming an alkyl ester from an alkane.

A chiral catalyst is disclosed together with methods of using it for enantioselective syntheses. The chiral catalyst includes a nucleus with two metal atoms that has four bridging ligands oriented radially to the axis of the nucleus. Each of these ligands includes a two complexing atoms each complexed to one of the metal atoms. At least one of the bridging ligands includes a chiral center which is bonded to one of the complexing atoms. Preferably, all four of the bridging ligands include a chiral center bonded to one of the complexing atoms. The catalyst of the invention has been found to be useful in catalyzing carbenoid transformation reactions such as cyclopropanation.

Disclosed are compound having the structure of formula (I):wherein M is Pt, Pd or Ni; Q is As, Sb or Bi; Z1 is N; Z2 is O or S; L1 and L2 are independently C(O), C—R1 or C—R2; X is a Lewis base and Y1 and Y2 are independently oxygen- or sulfur-containing substituents, conjugates containing compounds of formula (I) and their use as chemotherapy agents.

The invention discloses an industrial production method of miriplatin. The method comprises the following steps: dropwise adding an aqueous solution of cis-dinitric acid[(1R,2R)-1,2-diaminocyclohexane-dihydrate]paltinum (II) into a substrate solution containing myristic acid, alkali metal hydroxide and water, stirring and reacting for 8-36 h at 40-80 DEG C after dropwise adding, adding alkyl alcohol as a disperse solvent during aftertreatment, stirring and dispersing at 20-80 DEG C for 0.5-3 h, and filtering to obtain miriplatin, wherein the alkali metal hydroxide is sodium hydroxide, potassium hydroxide or ammonium hydroxide, and the alkyl sulfhydrate is methanol, ethanol, isopropanol or n-butanol. According to the preparation method, haloalkanes such as chloroform, etc. are not used as a reaction solvent; the reaction is simple to operate by a reverse dripping method; the aftertreatment is simpler by using alkyl alcohol added after the reaction as a disperse solvent; and the miriplatin prepared by the above method has high quality, is low-cost and is easier for large-scale industrial production.

Disclosed are compound having the structure of formula (I):wherein M is Pt, Pd or Ni; Q is As, Sb or Bi; Z1 is N; Z2 is O or S; L1 and L2 are independently C(O), C—R1 or C—R2; X is a Lewis base and Y1 and Y2 are independently oxygen- or sulfur-containing substituents, conjugates containing compounds of formula (I) and their use as chemotherapy agents.

A drug containing a metal-salen complex compound which is effective for a brain tumor is provided. The present invention is an anti-brain-tumor drug containing a metal-salen complex compound represented by the following Chemical Formula (I). In the formula, M represents a metal atom which is Fe, Cr, Mn, Co, Ni, Mo, Ru, Rh, Pd, W, Re, Os, Ir, Pt, Nd, Sm, Eu, or Gd, and X represents a halogen atom.

The present invention is directed to a method of alleviating, relieving, altering, remedying, ameliorating, improving or affecting a neoplastic disease or an immune disease, the method comprising administering to a subject in need thereof an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof:wherein P, Z, and m are defined herein above.

A drug containing a metal-salen complex compound which is effective for a brain tumor is provided. The present invention is an anti-brain-tumor drug containing a metal-salen complex compound represented by the following Chemical Formula (I). In the formula, M represents a metal atom which is Fe, Cr, Mn, Co, Ni, Mo, Ru, Rh, Pd, W, Re, Os, Ir, Pt, Nd, Sm, Eu, or Gd, and X represents a halogen atom.

Disclosed is a drug that contains as the primary component a metal-salen complex compound that is effective against brain tumors. The anti-brain-tumor drug contains a metal-salen complex compound represented by the belowmentioned chemical formula (I). In the formula, M is a metal atom comprising Fe, Cr, Mn, Co, Ni, Mo, Ru, Rh, Pd, W, Re, Os, Ir, Pt, Nd, Sm, Eu, or Gd, and X is a halogen atom.

The present invention discloses an iridium complexes and the organic EL device employing the iridium complexes as light emitting guest of emitting layer can display good performance like as lower driving voltage and power consumption, increasing efficiency and half-life time. Additional, the present invention provide the suitable emitting host (H1 to H6) to collocate with the energy level of iridium complexes for the present invention. Also provided a novel preparation method to synthesize the novel ligand such as 6-bromo-3,3-dimethyl-1-phenyl-1,3-dihydroindeno[2,1-b]carbazole.

The invention relates to a Pt2M heterotrinuclear metal organic alkyne coordination compound, wherein the structure of the Pt2M heterotrinuclear metal organic alkyne coordination compound is represented by the following formula (I): [Pt2M([mu]-PR2CH2PRCH2PR2)2(C[triple bond]CR')2(C[triple bond]CR'')2]<+>mA<m->, [mu] represents bridging, pR2CH2PRCH2PR2 is a class of tridentate phosphine ligands, andthe subscript numbers of the letters represent the number of groups. The invention also provides a preparation method and application of the Pt2M heterotrinuclear metal organic alkyne coordination compound. According to the invention, the coordination compound has phosphorescence emission, the color distribution of the emitted light is wide and ranges from blue green to orange red, and the coordination compound can be used as a photoluminescence material to be applied to the fields of display, illumination, sensing and biomarkers; and the copper coordination compound further has a self-recovery photochromic property, the colorless or light-color state is rapidly converted into a dark-color state through ultraviolet irradiation, the initial colorless or light-color state is gradually recovered after ultraviolet irradiation is stopped, and the self-recovery photochromic phenomenon has important application value in the fields of anti-counterfeiting and information encryption and decryption.

The present invention is in relation to the fields of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to improved methods for preparing lipid- conjugated platinumcompounds with high purity and good yields. The present disclosure also relates to nanoparticles comprising lipid-conjugated platinum compounds with high drug loading efficiency for use in chemotherapy, and to methods for producing said nanoparticles.

The present invention relates to the compositions containing dicycloplatin, pharmaceutical use of the compositions in the treatment and / or prevention of pain, inflammation and virus-related diseases, and methods of preparing the compostions thereof.

Disclosed herein are conjugates that include a ligand, and a compound having the structure of formula (I)M is Pt, Pd or Ni; Q is As, Sb or Bi; Z1 is N; Z2 is O or S; L1 and L2 are independently C(O), C—R1 or C—R2; X is a Lewis base; Y1 and Y2 are independently selected from —OR3, —OR4, —SR3 and —SR4, wherein R1 and R2 are independently selected from hydrogen, halogen, cyano, keto, ester, ether, thiol, thioether, thioester, imino, C1-C10 alkyl, C1-C10 alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C3-C15 cycloalkyl, heteroaryl, and C3-C15 heterocycloalkyl; and R3 and R4 are independently selected from hydrogen, C1-C10 alkyl, C1-C10 alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C3-C15 cycloalkyl, heteroaryl, and C3-C15 heterocycloalkyl.

Disclosed herein are methods of treating a cancer cell that include contacting a cancer cell with a compound having the structure of formula (I)M is Pt, Pd or Ni; Q is As, Sb or Bi; Z1 is N; Z2 is O or S; L1 and L2 are independently C(O), C—R1 or C—R2; X is a Lewis base; Y1 and Y2 are independently selected from —OR3, —OR4, —SR3 and —SR4, wherein R1 and R2 are independently selected from hydrogen, halogen, cyano, keto, ester, ether, thiol, thioether, thioester, imino, C1-C10 alkyl, C1-C10 alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C3-C15 cycloalkyl, heteroaryl, and C3-C15 heterocycloalkyl; and R3 and R4 are independently selected from hydrogen, C1-C10 alkyl, C1-C10 alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C3-C15 cycloalkyl, heteroaryl, and C3-C15 heterocycloalkyl.

Disclosed herein are conjugates that include a ligand, and a compound having the structure of formula (I)M is Pt, Pd or Ni; Q is As, Sb or Bi; Z1 is N; Z2 is O or S; L1 and L2 are independently C(O), C—R1 or C—R2; X is a Lewis base; Y1 and Y2 are independently selected from —OR3, —OR4, —SR3 and —SR4, wherein R1 and R2 are independently selected from hydrogen, halogen, cyano, keto, ester, ether, thiol, thioether, thioester, imino, C1-C10 alkyl, C1-C10 alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C3-C15 cycloalkyl, heteroaryl, and C3-C15 heterocycloalkyl; and R3 and R4 are independently selected from hydrogen, C1-C10 alkyl, C1-C10 alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C3-C15 cycloalkyl, heteroaryl, and C3-C15 heterocycloalkyl.

The present invention relates to the fields of nanotechnology and cancer therapy. In particular, the present disclosure relates to improved methods for preparing lipid-bound platinum compounds with high purity and good yield. The present disclosure also relates to nanoparticles comprising lipid-bound platinum compounds with high drug loading efficiency for use in chemotherapy, and methods of producing the nanoparticles.

The present disclosure provides platinum-containing conjugates that selectively target and kill tumor / cancer cells. The conjugates contain a moiety that selectively targets COX-2, which is overexpressed by a broad range of tumor / cancer cells.

The present invention discloses a novel catalyst having amine ligands for synthesizing methanol or its precursor. When the catalyst is allowed to react with an alkane in the presence of an acid, and at least one C-H bond of the alkane is catalytically oxidized. Therefore, the catalyst is suitable for use in forming an alkyl ester from an alkane.

The present invention relates to a Pt 2 M heterotrinuclear metal organic alkyne complex, its structure is as shown in the following formula (I): [Pt 2 M(μ‑PR 2 CH 2 PRCH 2 PR 2 ) 2 (C≡CR') 2 (C≡CR") 2 ] + m A m‑ ; (I) wherein, μ represents bridge connection; PR 2 CH 2 PRCH 2 PR 2 It is a kind of tridentate phosphine ligand; the subscript numbers of letters indicate the number of groups. In addition, the present invention also provides its preparation method and use. The complex has phosphorescence emission, and the color distribution of the emitted light is wide, ranging from blue-green to orange-red, and can be used as a photoluminescence material in the fields of display, illumination, sensing and biomarking. Among them, the copper complex also has self-recovery photochromic properties. The colorless or light-colored state is rapidly transformed into a dark state by ultraviolet light irradiation, and the original colorless or light-colored state is gradually restored when the ultraviolet light irradiation is stopped. This self-recovery photochromic phenomenon has important application value in the fields of anti-counterfeiting and information encryption and decryption.

The invention discloses a method for preparing oxaliplatin. The method comprises the following steps: I, performing reaction on tertpotassium chloroplatinite, potassium iodide and (1R,2R)-cyclohexanediamine to prepare diiododiam mineplatinumg; II, performing reaction on diiododiam mineplatinum obtained in the step I, and cuprous nitrate so as to obtain a nitrate middle body of amine platinum; and III, performing reaction on the nitrate middle body of the step II and sodium oxalate, thereby preparing oxaliplatin. By adopting the method, the production cost can be reduced, the medical expense of patients is reduced, the side effect is alleviated, and the yield is relatively high.

Novel catalysts with amine ligands for the synthesis of methanol or its precursors are disclosed. When the catalyst is reacted with an alkane in the presence of an acid, at least one C-H bond of the alkane is catalytically oxidized. Thus, the catalyst is suitable for the formation of alkyl esters from alkanes.